[Pharmacological and clinical profile of Cetuximab Injection (Erbitux)]

Nihon Yakurigaku Zasshi. 2009 Jun;133(6):341-8. doi: 10.1254/fpj.133.341.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Humanized
  • Antibody-Dependent Cell Cytotoxicity / drug effects
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Cycle / drug effects
  • Cell Division / drug effects
  • Cetuximab
  • Clinical Trials as Topic
  • Colonic Neoplasms / blood supply
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / pathology
  • DNA Repair / drug effects
  • ErbB Receptors / immunology*
  • Humans
  • Immunoglobulin G
  • Mutation
  • Neovascularization, Pathologic
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins / genetics

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Immunoglobulin G
  • KRAS protein, human
  • Proto-Oncogene Proteins
  • ErbB Receptors
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins
  • Cetuximab